New Insight for the Treatment of Follicular Lymphoma in Relapse: The Role of Obinutuzumab

In patients who relapse early in the course of treatment, patients with low grade lymphoma need new standards since most patients become resistant to subsequent treatment. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. Recently, with data accumulation treatment options moved